CXCR4

CXCR4

CXCR4 (C-X-C chemokine receptor type 4) is a G protein-coupled receptor (GPCR) that is encoded by the CXCR4 gene in humans. It is a receptor for the chemokine CXCL12, also known as stromal cell-derived factor 1 (SDF-1). CXCR4 plays a crucial role in various physiological and pathological processes, including immune response, hematopoiesis, and cancer metastasis.

Structure

CXCR4 is a member of the chemokine receptor family, which is characterized by seven transmembrane domains. The receptor is composed of 352 amino acids and has an extracellular N-terminus, seven transmembrane helices, and an intracellular C-terminus. The binding of CXCL12 to CXCR4 induces a conformational change that activates intracellular signaling pathways.

Function

CXCR4 is primarily expressed on the surface of hematopoietic stem cells, lymphocytes, and other immune cells. It is involved in the homing and retention of hematopoietic stem cells in the bone marrow. CXCR4 also plays a role in the migration of immune cells to sites of inflammation.

In addition to its role in the immune system, CXCR4 is implicated in the development and progression of various cancers. It is overexpressed in many tumor types and is associated with increased tumor invasiveness and metastasis. The CXCL12/CXCR4 axis is a key regulator of cancer cell migration and metastasis.

Clinical Significance

HIV Infection

CXCR4 serves as a co-receptor for HIV entry into CD4+ T cells. The virus uses CXCR4, along with CCR5, to gain entry into host cells. This has made CXCR4 a target for antiretroviral therapies aimed at blocking HIV entry.

Cancer

The overexpression of CXCR4 in cancer cells is associated with poor prognosis and increased metastatic potential. Inhibitors of CXCR4 are being investigated as potential therapeutic agents in cancer treatment. These inhibitors aim to block the interaction between CXCL12 and CXCR4, thereby reducing tumor cell migration and metastasis.

Other Diseases

Mutations in the CXCR4 gene are associated with WHIM syndrome, a rare immunodeficiency disorder characterized by warts, hypogammaglobulinemia, infections, and myelokathexis.

Therapeutic Targeting

Several CXCR4 antagonists are in development or clinical trials for the treatment of cancer and other diseases. These include small molecules, peptides, and monoclonal antibodies that block the CXCL12/CXCR4 interaction.

Research

Ongoing research is focused on understanding the precise mechanisms by which CXCR4 contributes to disease processes and how it can be effectively targeted in therapy. Studies are also exploring the role of CXCR4 in stem cell mobilization and tissue regeneration.

See Also

• Chemokine receptor
• G protein-coupled receptor
• HIV
• Cancer metastasis

External Links

• CXCR4 Gene - NCBI
• CXCR4 - UniProt